MELISSA VERZURA: Open Payments
NPI 1932690278 · MIAMI BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,171 in 47 payments from 17 companies in 2025. Trend: 2023 $2,830 · 2024 $2,446 · 2025 $1,171
Food & beverage: $1,171
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $214 |
| Alkermes, Inc. | 6 | $147 |
| E.R. Squibb & Sons, L.L.C. | 4 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $104 |
| Eisai Inc. | 3 | $100 |
| Vanda Pharmaceuticals Inc. | 3 | $94 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| Lundbeck LLC | 3 | $59 |
| ABBVIE INC. | 2 | $37 |
Products named: UZEDY, ARISTADA, REXULTI, Leqembi, CAPLYTA, HETLIOZ, COBENFY, Auvelity.
Industry payments across FL — which companies pay providers there.
